metformin + sitagliptin + glimepiride

Metformin + sitagliptin + glimepiride is a fixed-dose combination of three oral antidiabetic agents used for the treatment of type 2 diabetes mellitus in adults. Each component has a distinct mechanism of action: - Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity. - Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), leading to increased insulin release from pancreatic beta cells and decreased glucagon secretion from alpha cells in response to meals. - Glimepiride is a sulfonylurea that stimulates pancreatic beta cells to secrete more insulin and enhances peripheral tissue sensitivity to insulin. The combination targets multiple pathophysiological defects in type 2 diabetes, providing complementary glycemic control. It is indicated for patients whose blood sugar levels are inadequately controlled on monotherapy or dual therapy with these agents[1][5].

Brand names

Glimiprime-SM1 ForteGlimiprime-SM-1 ForteGlimiprime-SM 1 ForteGlimiprime-SM2 ForteGlimiprime-SM-2 ForteGlimiprime-SM 2 Forte

Other names

sitagliptin + glimepiride + metforminglimepiride + metformin + sitagliptin